C07K 2317/76
Antagonist effect on antigen
Official title: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K2317/76 (Antagonist effect on antigen) appears on 12,218 US grants and 23,943 published applications in this corpus.
Search patents in C07K- Granted patents
- 12,218
- Published applications
- 23,943
- Assignees
- 5,026
- Inventors
- 32,018
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 7 | 0 |
| 1999 | 9 | 0 |
| 2000 | 21 | 0 |
| 2001 | 24 | 9 |
| 2002 | 27 | 72 |
| 2003 | 23 | 103 |
| 2004 | 26 | 101 |
| 2005 | 26 | 205 |
| 2006 | 70 | 271 |
| 2007 | 82 | 319 |
| 2008 | 113 | 316 |
| 2009 | 156 | 522 |
| 2010 | 230 | 590 |
| 2011 | 301 | 735 |
| 2012 | 371 | 732 |
| 2013 | 487 | 878 |
| 2014 | 547 | 1033 |
| 2015 | 645 | 1205 |
| 2016 | 727 | 1443 |
| 2017 | 809 | 1433 |
| 2018 | 810 | 1381 |
| 2019 | 890 | 1529 |
| 2020 | 943 | 1568 |
| 2021 | 909 | 1757 |
| 2022 | 883 | 1762 |
| 2023 | 770 | 1605 |
| 2024 | 878 | 1804 |
| 2025 | 859 | 1513 |
| 2026 | 568 | 1057 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Antibodies against human TSLP and use thereof6 Oct 2026US 12,753,227 B2Beijing Wisdomab Biotechnology Co., Ltd
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Antibody recognizing extracellular region of ALK2/ACVR16 Oct 2026US 12,753,237 B2Saitama Medical University
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Thin Wall Cannula8 Oct 2026US 2026/0306753 A1Becton, Dickinson and Company
- Methods and compositions for treating cancer8 Oct 2026US 2026/0308241 A1Chugai Seiyaku Kabushiki Kaisha
- Methods of treating inflammatory diseases8 Oct 2026US 2026/0308246 A1Boehringer Ingelheim International GmbH
- Selective reduction of cysteine residues in il-17 antibodies8 Oct 2026US 2026/0308247 A1Novartis AG
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Antibodies to human programmed death receptor PD-1454US 8,354,509 B2MSD Oss B.V. · 2013